Gemini Therapeutics Inc. Common Stock
(NASDAQ:GMTX)
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.
GMTX Overview
None
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$1.5400 |
Previous Close Volume |
24650 |
Latest News
- GATX Corporation Sets Date for 2021 First Quarter Earnings Release and Conference Call CHICAGO , April 05, 2021 (GLOBE NEWSWIRE) -- GATX Corporation (NYSE:GATX) will report results for the 2021 first quarter prior to market open on April 20, 2021 . GATX will hold a conference call to review the results later that morning. Investors may listen to the call via telephone or over the 05 Apr 2021 18:47:48